JP2025504447A - アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療 - Google Patents

アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療 Download PDF

Info

Publication number
JP2025504447A
JP2025504447A JP2024542395A JP2024542395A JP2025504447A JP 2025504447 A JP2025504447 A JP 2025504447A JP 2024542395 A JP2024542395 A JP 2024542395A JP 2024542395 A JP2024542395 A JP 2024542395A JP 2025504447 A JP2025504447 A JP 2025504447A
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
days
acid
diethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024542395A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025504447A5 (enExample
Inventor
チョンシ ユ
リナ スー
Original Assignee
テックフィールズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テックフィールズ インコーポレイテッド filed Critical テックフィールズ インコーポレイテッド
Publication of JP2025504447A publication Critical patent/JP2025504447A/ja
Publication of JP2025504447A5 publication Critical patent/JP2025504447A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/625—Salicylic acid; Derivatives thereof having heterocyclic substituents, e.g. 4-salicycloylmorpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024542395A 2022-01-17 2023-01-12 アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療 Pending JP2025504447A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2022/072270 2022-01-17
CN2022072270 2022-01-17
PCT/CN2023/071973 WO2023134732A1 (en) 2022-01-17 2023-01-12 Prevention or treatment of cardiovascular diseases with high penetration prodrugs of aspirin and other nsaids

Publications (2)

Publication Number Publication Date
JP2025504447A true JP2025504447A (ja) 2025-02-12
JP2025504447A5 JP2025504447A5 (enExample) 2026-02-17

Family

ID=87280122

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024542395A Pending JP2025504447A (ja) 2022-01-17 2023-01-12 アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療

Country Status (10)

Country Link
US (1) US20250099491A1 (enExample)
EP (1) EP4465993A4 (enExample)
JP (1) JP2025504447A (enExample)
KR (1) KR20250005055A (enExample)
CN (1) CN118632699A (enExample)
AU (1) AU2023206720A1 (enExample)
CA (1) CA3252370A1 (enExample)
IL (1) IL314290A (enExample)
TW (1) TW202339711A (enExample)
WO (1) WO2023134732A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118373749A (zh) * 2024-04-29 2024-07-23 四川施成收生态科技有限公司 一种含有2-羟基苯甲酸-2-（二乙氨基）乙酯结构的化合物制备及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH399486A (fr) * 1962-10-02 1965-09-30 Biosedra Lab Procédé de préparation de nouvelles salicylamides
CA2656858C (en) * 2006-07-09 2016-01-19 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of acetylsalicylic acid
CN101500983B (zh) * 2006-07-26 2015-09-16 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性二氟尼柳及相关化合物的前药
CN111012914A (zh) * 2012-01-18 2020-04-17 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
CN112521305B (zh) * 2013-03-15 2023-04-25 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物

Also Published As

Publication number Publication date
US20250099491A1 (en) 2025-03-27
WO2023134732A1 (en) 2023-07-20
TW202339711A (zh) 2023-10-16
EP4465993A4 (en) 2026-01-07
KR20250005055A (ko) 2025-01-09
WO2023134732A9 (en) 2024-08-08
EP4465993A1 (en) 2024-11-27
AU2023206720A1 (en) 2024-08-29
IL314290A (en) 2024-09-01
CN118632699A (zh) 2024-09-10
CA3252370A1 (en) 2023-07-20

Similar Documents

Publication Publication Date Title
AU2004233587B2 (en) Use of a topical medicament comprising Riluzole
JP6262225B2 (ja) オキサビシクロヘプタン類、および再灌流障害の治療のためのオキサビシクロヘプタン類
MX2008003882A (es) Formulacion de capsula de pirfenidona y excipientes farmaceuticamente aceptables.
CN105143174A (zh) 治疗帕金森疾病的新型高穿透力药物和医药组合物
CN114728919B (zh) MrgprX2拮抗剂及其用途
JP5788527B2 (ja) キナーゼ阻害剤の副作用低減剤
JP2018507874A (ja) 過剰な体脂肪の治療処置または美容処置のためのｎｋ−３受容体拮抗薬
PT2054051E (pt) Utilização de derivados 2,5-di-hidroxibenzeno para tratar ceratose actínica
TW202128729A (zh) 新肽及其在炎症治療中的用途
JP2025504447A (ja) アスピリン及びその他のｎｓａｉｄの高透過プロドラッグによる心血管疾患の予防又は治療
JP2022504184A (ja) ブドウ膜黒色腫の治療のための併用療法
ES2237625T3 (es) Uso de un derivado de hidantoina en una composicion farmaceutica contra la hipoalbuminemia.
CN104902891B (zh) 治疗和预防创伤性脑损伤性神经元损害的组合物和方法
CN108904481B (zh) 邻羟基查尔酮类似物在制备抗氧化药物中的应用
CN117379423A (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
JP2014508740A (ja) 治療用冷却剤組成物における溶媒としての使用のための（ｒ）−１，２−プロパンジオール
CN106946866A (zh) 一种预防和治疗脑卒中的药物及其制备方法
EP4176873A1 (en) Urinary symptom therapeutic agent
JP7418502B2 (ja) 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用
JP7257091B2 (ja) 認知症の治療及び予防薬
KR20140037045A (ko) 치료적 쿨링제 조성물에서 용매로서 사용하기 위한 (r)-1,2-프로판디올
TW202535906A (zh) 新型短鏈肽及其衍生物
JPWO2005058878A1 (ja) 月経困難症の予防および／または治療剤
TW202214249A (zh) 紫質症之預防或治療劑
JPS61172820A (ja) カルシウム拮抗剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251223

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251223